KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBT Margin (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of EBT Margin data on record, last reported at 0.29% in Q4 2025.

  • For Q4 2025, EBT Margin fell 1334.0% year-over-year to 0.29%; the TTM value through Dec 2025 reached 2.32%, up 1133.0%, while the annual FY2025 figure was 2.32%, 1133.0% up from the prior year.
  • EBT Margin reached 0.29% in Q4 2025 per PCRX's latest filing, down from 5.31% in the prior quarter.
  • Across five years, EBT Margin topped out at 22.34% in Q2 2023 and bottomed at 82.37% in Q3 2024.
  • Average EBT Margin over 5 years is 2.85%, with a median of 6.73% recorded in 2024.
  • Peak YoY movement for EBT Margin: plummeted -9250bps in 2024, then surged 8768bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 3.89% in 2021, then crashed by -174bps to 10.67% in 2022, then skyrocketed by 274bps to 18.6% in 2023, then decreased by -27bps to 13.63% in 2024, then plummeted by -98bps to 0.29% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 0.29% in Q4 2025, 5.31% in Q3 2025, and 1.06% in Q2 2025.